Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin


      An estimated 750,000 melanoma survivors in the United States are at increased risk of subsequent primary cancers.


      We sought to assess the risk of developing subsequent primary cancers among people with cutaneous melanoma.


      Using 1992 to 2006 data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program, 40,881 people with in situ melanoma and 76,041 people with invasive melanoma were followed up (mean of 5.6 years) for the development of subsequent primary cancers. The observed number of subsequent cancers was compared with those expected based on age-/race-/year-/site-specific rates in the Surveillance, Epidemiology, and End Results population. Standardized incidence ratios (SIRs) (SIR = observed number/expected number) were considered statistically significant if they differed from 1, with an alpha level of 0.05.


      After a first primary in situ melanoma, risk was significantly elevated for subsequent invasive melanoma and chronic lymphocytic leukemia among men (SIRs = 8.43 and 1.44, respectively) and women (SIRs = 12.33 and 1.79, respectively). After a first primary invasive melanoma, risk was significantly elevated for subsequent invasive melanoma, thyroid cancer, non-Hodgkin lymphoma, and chronic lymphocytic leukemia among both men (SIRs = 12.50, 2.67, 1.56, and 1.57, respectively) and women (SIRs = 15.67, 1.77, 1.42, and 1.63, respectively).


      Case ascertainment issues particularly affecting in situ melanoma cases could affect results. The role of detection bias in the diagnoses of some subsequent cancers cannot be completely eliminated.


      The findings of the study should guide the development of strategies such as posttreatment surveillance, screening, and ultraviolet exposure education among melanoma survivors to improve cancer survivorship.

      Key words

      Abbreviations used:

      AER ( absolute excess risk), CLL ( chronic lymphocytic leukemia), NHL ( non-Hodgkin lymphoma), PY ( person-years), SEER ( Surveillance, Epidemiology, and End Results), SIR ( standardized incidence ratio), UV ( ultraviolet)


      1. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al. SEER cancer statistics review, 1975-2006. Available from: URL: Accessed April 9, 2011.

        • Elwood J.M.
        • Hislop T.G.
        Solar radiation in the etiology of cutaneous malignant melanoma in Caucasians.
        Natl Cancer Inst Monogr. 1982; 62: 162-171
        • Lee J.A.H.
        Melanoma and exposure to sunlight.
        Epidemiol Rev. 1982; 4: 110-136
        • Holman C.D.
        • Armstrong B.K.
        Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenic types.
        J Natl Cancer Inst. 1984; 73: 75-82
        • Gallagher R.P.
        • Elwood J.M.
        • Hill G.B.
        Risk factors for cutaneous malignant melanoma: the Western Canada melanoma study.
        in: Gallagher R.P. Epidemiology of malignant melanoma. Springer-Verlag, Berlin1986: 38-55
        • Kricker A.
        • Armstrong B.K.
        • Goumas C.
        • Litchfield M.
        • Begg C.B.
        • Hummer A.J.
        • et al.
        Ambient UV, personal sun exposure and risk of multiple primary melanomas.
        Cancer Causes Control. 2007; 18: 295-304
        • Tuohimaa P.
        • Pukkala E.
        • Scelo G.
        • Olsen J.H.
        • Brewster D.H.
        • Hemminki K.
        • et al.
        Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancer: vitamin D as a possible explanation.
        Eur J Cancer. 2007; 43: 1701-1712
        • Hayat M.J.
        • Howlander N.
        • Reichman M.E.
        • Edwards B.K.
        Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) program.
        Oncologist. 2007; 12: 20-37
        • Freedman D.M.
        • Miller B.A.
        • Tucker M.A.
        New malignancies following melanoma of the skin, eye melanoma, and non-melanoma eye cancer. SEER cancer registries, 1973-2000. NIH publication No. 05-5302.
        National Cancer Institute, Bethesda (MD)2006 (p. 339-62)
        • Bradford P.T.
        • Freedman D.M.
        • Goldstein A.M.
        • Tucker M.A.
        Increased risk of second primary cancers after a diagnosis of melanoma.
        Arch Dermatol. 2010; 146: 265-272
        • Crocetti E.
        • Guzzinati S.
        • Paci E.
        • Falcini F.
        • Zanetti R.
        • Vercelli M.
        • et al.
        The risk of developing a second, different, cancer among 14560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian network of cancer registries).
        Melanoma Res. 2008; 18: 230-234
        • Cantwell M.M.
        • Murray L.J.
        • Catney D.
        • Donnelly D.
        • Autier P.
        • Boniol M.
        • et al.
        Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland.
        Br J Cancer. 2009; 100: 174-177
        • Hall P.
        • Rosendahl I.
        • Mattsson A.
        • Einhorn S.
        Non-Hodgkin's lymphoma and skin malignancies–shared etiology?.
        Int J Cancer. 1995; 62: 519-522
        • Bhatia S.
        • Estrad-Batres L.
        • Maryon T.
        • Bogue M.
        • Chu D.
        Second primary tumors in patients with cutaneous malignant melanoma.
        Cancer. 1999; 86: 2014-2020
        • Goggins W.B.
        • Tsao H.
        A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors.
        Cancer. 2003; 97: 639-643
        • Guerin S.
        • Dupuy A.
        • Anderson H.
        • Shamsaldin A.
        • Svahn-Tapper G.
        • Moller T.
        • et al.
        Radiation dose as a risk factor for malignant melanoma following childhood cancer.
        Eur J Cancer. 2003; 39: 2379-2386
        • Wassberg C.
        • Thorn M.
        • Yuen J.
        • Hakulinen T.
        • Ringborg U.
        Cancer risk in patients with earlier diagnosis of cutaneous melanoma in situ.
        Int J Cancer. 1999; 83: 314-317
      2. Johnson C.H. SEER program coding and staging manual 2004, revision 1. NIH publication No. 04-5581. National Cancer Institute, Bethesda (MD)2004
        • Ahmed F.
        • Goodman M.T.
        • Kosary C.
        • Ruiz B.
        • Wu X.
        • Chen V.W.
        • et al.
        Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975-2001.
        Cancer. 2006; 107: 1162-1171
        • Fountain J.W.
        • Karajiorgou M.
        • Ernstoff M.S.
        • Kirkwood J.M.
        • Vlock D.R.
        • Titus-Ernstoff L.
        • et al.
        Homozygous deletions within human chromosome band 9p21 in melanoma.
        Proc Nat Acad Sci. 1992; 89: 10557-10561
        • Pollack C.
        • Hagemeijer A.
        Abnormalities of the short arm of chromosome 9 with partial loss of materials in hematological disorders.
        Leukemia. 1987; 1: 541-548
      3. National Comprehensive Cancer Network. Melanoma: clinical practice guidelines in oncology. Available from: URL: Accessed March 23, 2011.

        • Francken A.B.
        • Bastiaannet E.
        • Heokstra H.J.
        Follow-up in patients with localized primary cutaneous melanoma.
        Lancet Oncol. 2005; 6: 608-621
        • Poo-Hwu W.J.
        • Ariyan S.
        • Lamb L.
        • Papac R.
        • Zelterman D.
        • Hu G.L.
        • et al.
        Follow-up recommendations for patients with American Joint Committee on Cancer stages I-III malignant melanoma.
        Cancer. 1999; 86: 2252-2258
        • Brobreil A.
        • Rapaport D.
        • Wells K.
        • Cruse C.W.
        • Glass F.
        • Fenske N.
        • et al.
        Multiple primary melanomas: implications for screening and follow-up programs for melanoma.
        Ann Surg Oncol. 1997; 4: 19-23
        • Uliasz A.
        • Lebwohl M.
        Patient education and regular surveillance results in earlier diagnosis of second primary melanoma.
        Int J Dermatol. 2007; 46: 575-577
        • Abbasi N.R.
        • Shaw H.M.
        • Rigel D.S.
        • Friedman R.J.
        • McCarthy W.H.
        • Osman I.
        • et al.
        Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria.
        JAMA. 2004; 292: 2771-2776